Busan, South Korea

Sillajen, Inc.


USPTO Granted Patents = 4


Trademarks = 1

Forward Citations = 3

Loading Chart...
Loading Chart...

13 inventors (with patents filed for the assignee):

goldMedal John Cameron Bell (2 out of 30 patents)

silverMedal Nam Hee Lee (2 out of 2 patents)

bronzeMedal Caroline Breitbach (2 out of 4 patents)

4.  Anne Moon (2 out of 2 patents)

5.  Tae-Ho Hwang (2 out of 2 patents)

6.  Yu Kyoung Lee (2 out of 2 patents)

7.  Mi-kyung Kim (2 out of 2 patents)

8.  Tae Ho Hwang (2 out of 3 patents)

9.  David H Kirn (2 out of 19 patents)

10.  Euna Cho (1 out of 1 patent)

11.  Mong Cho (1 out of 1 patent)

12.  Ungbae Jeon (1 out of 1 patent)

13.  Doo Jin Byun (1 out of 3 patents)

14.  Hongjae Jeon (0 patent)

15.  Eun Sang Moon (0 patent)


4 patents:

Company Overview
Sillajen, Inc. is a biotechnology company focused on developing and commercializing oncolytic immunotherapy products for the treatment of cancer. Their lead product candidate, Pexa-Vec, is currently in clinical trials for various types of cancer. Sillajen is dedicated to advancing innovative therapies to improve the lives of patients with cancer.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

4 Patents

#42 in Busan

#2,200 in South Korea

Busan, KR
Busan, South Korea
Forward Citations = 3

13 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Sillajen, Inc.. Retrieved from https://idiyas.com/company/sillajen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…